NCT00805454View on ClinicalTrials.gov

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Schizophrenia
Interventions
DRUG

OPC-34712

Single oral dose, 0.5 to 25 mg

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY